ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action - CORT

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval [5]. - Defendants indicated confidence in the NDA submission and communicated with the FDA, asserting no anticipated obstacles to approval, despite the FDA's concerns regarding the clinical evidence [5]. - The lawsuit claims that when the true situation regarding the NDA was revealed, investors suffered damages due to the misrepresentation [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].